Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 7/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28427280 | 1.00 | EPHX1 (0.67) | EPHX1KDM4EMAPK1HIF1ATDP1 | |
| SCHEMBL2050973 | 0.98 | EPHX1 (0.63) | EPHX1KDM4EMAPK1HIF1ATDP1 | |
| SCHEMBL2042986 | 0.91 | — | — | |
| SCHEMBL717081 | 0.89 | EPHX1 (0.82) | EPHX1KDM4EMAPK1HIF1ATDP1 | |
| SCHEMBL14252129 | 0.89 | EPHX1 (0.82) | EPHX1KDM4EMAPK1HIF1ATDP1 | |
| SCHEMBL7788927 | 0.89 | EPHX1 (0.82) | EPHX1KDM4EMAPK1HIF1ATDP1 | |
| SCHEMBL7788937 | 0.89 | EPHX1 (0.82) | EPHX1KDM4EMAPK1HIF1ATDP1 | |
| SCHEMBL7788569 | 0.89 | EPHX1 (0.82) | EPHX1KDM4EMAPK1HIF1ATDP1 | |
| SCHEMBL7252127 | 0.86 | EPHX1 (0.77) | EPHX1KDM4EMAPK1HIF1ATDP1 | |
| SCHEMBL23735485 | 0.82 | EPHX1 (0.72) | EPHX1KDM4EMAPK1HIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256471-B1 | NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2018-12-12 | — | — | EP | claimed |
| US-10093671-B2 | 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-10-09 | — | — | US | claimed |
| EP-3256471-A1 | NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-12-20 | — | — | EP | claimed |
| US-20170342069-A1 | NOVEL 2-OXO-6, 7-DIHYDROBENZO[a]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-11-30 | — | — | US | claimed |
| WO-2016128335-A1 | NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-08-18 | — | — | WO | claimed |
| EP-3256471-B1 | NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2018-12-12 | — | — | EP | disclosed |
| US-10093671-B2 | 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| EP-3256471-A1 | NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| US-20170342069-A1 | NOVEL 2-OXO-6, 7-DIHYDROBENZO[a]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2016128335-A1 | NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-08-18 | — | — | WO | disclosed |
| EP-2325167-A1 | METHOD FOR PRODUCING CARBAMATE COMPOUND | Ube Industries, Ltd. (JP) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342069-A1 | NOVEL 2-OXO-6, 7-DIHYDROBENZO[a]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP2B6, CYP2A6 | EPHX1 1032/4885KDM4E 2672/4885MAPK1 2785/4885 |
| US-10093671-B2 | 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, CYP2B6, CYP2A6 | EPHX1 1049/4885KDM4E 2436/4885MAPK1 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.